Drugs / Omega-DEK
last change May 2026 re-read 2 minutes ago

Omega-DEK

Developed for
childhood apraxia of speech
Investigated by
Claudia R. Morris

Trials 1 · a red edge is where a trial was stopped

20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07216001 May 2026 → Dec 2027 expected autism, childhood apraxia of speech Claudia R. Morris Not yet recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Omega-DEK ClinicalTrials.gov intervention name — accepted as the source's own label NCT07216001